daunorubicin has been researched along with galantamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chmielewski, J; Emmert, D; Hrycyna, CA; Namanja, HA; Pires, MM | 1 |
1 review(s) available for daunorubicin and galantamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for daunorubicin and galantamine
| Article | Year |
|---|---|
Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Daunorubicin; Dimerization; Doxorubicin; Galantamine; Humans; Inhibitory Concentration 50; Verapamil | 2009 |